S., Riddle, M
Those with BMI of 27-29.9 accompanied by weight-related health conditions like type 2 diabetes, hypertension, or sleep apnea also fall within appropriate treatment parameters
Lilly recently reported topline results from the ATTAIN-1 phase-3 trial evaluating orforglipron, a once-daily oral glucagon-like-peptide-1 (GLP-1) receptor agonist for adults with obesity or overweight without diabetes
The most common are constipation, fatigue, headaches, indigestion, nausea, and vomiting
Regular follow-up appointments allow healthcare professionals to assess treatment response, adjust doses, monitor for complications, and provide ongoing support for lifestyle modifications that complement pharmacological therapy
One avocado contains around 13 grams of healthy fats and 10 grams of fiber